Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii

Parasites and Vectors

Volumn 6, Issue 1, 2013, Pages

  Cong, Hua ^a   Zhang, Min ^a   Xin, Qing ^b   Wang, Zhiyu ^c   Li, Ying ^a   Zhao, Qunli ^a   Zhou, Huaiyu ^a   He, Shenyi ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

CTXA2 B; DNA vaccination; SAG1; SAG3; Surface antigen; Toxoplasma gondii

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA TOXIN SUBUNIT A2; DNA; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; MEMBRANE ANTIGEN; PHOSPHATE BUFFERED SALINE; SAG1 ANTIGEN; SAG3 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DNA IMMUNIZATION; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; RECOMBINANT PLASMID; SPLEEN CELL; SURVIVAL; SURVIVAL RATE; T LYMPHOCYTE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA;

MUS; TOXOPLASMA GONDII;

EID: 84874805771     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-6-63     Document Type: Article

References (33)

1. Toxoplasma gondii infection in humans in China. Zhou P, Chen Z, Li HL, Zheng H, He S, Lin R, Zhu XQ, Parasit Vectors 2011 4 165 10.1186/1756-3305-4-165 21864327
2. The child with congenital toxoplasmosis. McLeod R, Boyer K, Roizen N, Curr Clin Top Infect Dis 2000 20 189 208 10943525
3. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier-Clerc M, Missé D, Thomas F, Infect Genet Evol 2012 12 2 496 498 10.1016/j.meegid.2012.01.013 22285308
4. Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar. Walle F, Kebede N, Tsegaye A, Kassa T, Northwest Ethiopia. Parasit Vectors 2013 6 15 10.1186/1756-3305-6-15
5. A commercial vaccine for ovine toxoplasmosis. Buxton D, Innes EA, Parasitol 1995 110 11 16 10.1017/S003118200000144X
6. Immune response and resistance to T. gondii in mice immunized with antigens of the parasite incorporated into immunostimulation complex. Lunden A, Lovgren K, Ugglaand A, Araujo FG, Infect Immun 1993 61 6 2639 8500902
7. Nucleic acid vaccination against Toxoplasma gondii in mice. Angus CW, J Eukaryot Microbiol 1996 43 5 117 118 10.1111/j.1550-7408.1996.tb05034.x
8. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Fachado A, Rodriguez A, Angel SO, Vaccine 2003 21 13-14 1327 1335 12615427 (Pubitemid 36266690)
9. DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice. Sun XM, Zou J, Elashram Saeed AA, Yan WC, Liu XY, Suo X, Wang H, Chen QJ, Parasit Vectors 2011 4 213 10.1186/1756-3305-4-213 22070984
10. The SAS superfamily of Toxoplasma surface proteins. Calvin J, Cleo Y, Lee F, Michael EG, Int J Parasitol 2004 34 285 296 10.1016/j.ijpara.2003.12.004 15003490 (Pubitemid 38299179)
11. Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice. Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H, Lu G, Zhao Q, Zhu XQ, Parasit Vectors 2012 5 273 10.1186/1756-3305-5-273 23181694
12. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Mévéle MN, Bout D, Desolme B, Vaccine 2005 23 36 4489 4499 10.1016/j.vaccine.2005.04.025 15935521 (Pubitemid 40967977)
13. Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes. Rabie MM, Fumie A, Mei C, Vaccine 2003 21 2852 2861 10.1016/S0264-410X(03)00157-9 12798627 (Pubitemid 36703196)
14. Similarities between the primary structures of two distinct major surface proteins of Toxoplasma gondii. Cesbron-Delauw MF, Tomavo S, Beauchamps P, Fourmaux MP, Camus D, Capron A, Dubremetz JF, J Biol Chem 1994 269 16217 16222 8206924 (Pubitemid 24209314)
15. The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S, Curr Top Microbiol Immunol 1996 219 45 54 8791687 (Pubitemid 26272943)
16. Surface antigens of Toxoplasma gondii: variations on a theme. Lekutis C, Ferguson DJ, Grigg ME, Camps M, Boothroyd JC, Int J Parasitol 2001 31 12 1285 1292 10.1016/S0020-7519(01)00261-2 11566296 (Pubitemid 32868708)
17. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD, Parasit Vectors 2013 6 34 10.1186/1756-3305-6-34 23398973
18. The surface antigen SAG3 mediates the attachment of Toxoplasma gondii to cell-surface proteoglycans. Jacquet A, Coulon L, De Neve J, Daminet V, Haumont M, Garcia L, Bollen A, Jurado M, Biemans R, Mol Biochem Parasitol 2001 116 35 44 10.1016/S0166-6851(01)00297-3 11463464 (Pubitemid 32706425)
19. Targeted disruption of the glycosylphosphatidylinositol-anchored surface antigen SAG3 gene in Toxoplasma gondii decreases host cell adhesion and drastically reduces virulence in mice. Dzierszinski F, Mortuaire M, Cesbron-Delauw MF, Tomavo S, Mol Microbiol 2000 37 574 582 10931351 (Pubitemid 30611838)
20. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. Angus CW, Klivington-Evans D, Dubey JP, Infect Dis 2000 181 317 324 10.1086/315186 (Pubitemid 30049063)
21. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Nielsen HV, Lauemoller SL, Christiansen L, Buus S, Fomsgaard A, Petersen E, Infect Immun 1999 67 12 6358 6363 10569750
22. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Couper KN, Nielsen HV, Petersen E, Roberts F, Roberts CW, Alexander J, Vaccine 2003 21 21-22 2813 2820 12798622 (Pubitemid 36703192)
23. Vaccination against murine Toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A. Lee YH, Shin DW, Lee JH, Nam HW, Ahn MH, Yonsei Med J 2007 48 3 396 404 10.3349/ymj.2007.48.3.396 17594146 (Pubitemid 47083084)
24. The mechanism of cholera toxin adjuvanticity. Lycke N, Res Immunol 1997 148 8-9 504 9588829
25. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Eriksson K, Fredriksson M, Nordstrom I, Holmgren J, Infect Immun 2003 71 4 1740 1747 10.1128/IAI.71.4.1740- 1747.2003 12654787 (Pubitemid 36368702)
26. Synergistic role of CD4§ssup§+§esup§ and CD8§ssup§+§esup§ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A, J Immunol 1991 146 286 292 1670604
27. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, D'Souza S, Vaccine 2010 28 2556 2564 10.1016/j.vaccine.2010.01.031 20117266
28. Importance of CD8(+)Vbeta8(+) T cells in IFN-gamma-mediated prevention of toxoplasmic encephalitis in genetically resistant BALB/c mice. Wang X, Claflin J, Kang H, Suzuki Y, J Interferon Cytokine Res 2005 25 6 338 344 10.1089/jir.2005.25.338 15957957 (Pubitemid 40911385)
29. Cytokines and chemokines production by mononuclear cells from parturient women after stimulation with live Toxoplasma gondii. Rezende-Oliveira K, Silva NM, Mineo JR, Rodrigues JV, Placenta 2012 33 9 682 687 10.1016/j.placenta.2012. 05.013 22742727
30. Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts. Zou J, Huang XX, Yin GW, Ding Y, Liu XY, Wang H, Chen QJ, Suo X, Parasit Vectors 2011 4 168 10.1186/1756-3305-4-168 21871123
31. Multicomponent DNA vaccine-encoding Toxoplasma gondii GRA1 and SAG1 primes: anti-Toxoplasma immune response in mice. Wu XN, Lin J, Lin X, Chen J, Chen ZL, Lin JY, Parasitol Res 2012 111 5 2001 2009 10.1007/s00436-012-3047-y 22837100
32. A comparative study of small RNAs in Toxoplasma gondii of distinct genotypes. Wang JL, Liu XL, Jia B, Lu H, Peng S, Piao X, Hou N, Cai P, Yin J, Jiang N, Chen Q, Parasit Vectors 2012 5 186 10.1186/1756-3305-5-186 22943187
33. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, Li HX, Lv ZC, Cheng T, Ren D, Yang GL, Lin RQ, Zhu XQ, Clin Vaccine Immunol 2012 19 12 1916 1920 10.1128/CVI.00397-12 23015648